Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.
作者信息
Prébet Thomas, Thepot Sylvain, Gore Steven D, Dreyfus François, Fenaux Pierre, Vey Norbert
机构信息
Department of Hematological Malignancies, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
出版信息
Haematologica. 2013 Feb;98(2):e18-9. doi: 10.3324/haematol.2012.071050. Epub 2012 Sep 14.
Abstract
摘要
相似文献
1
Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.阿扎胞苷治疗失败后低危骨髓增生异常综合征患者的预后
Haematologica. 2013 Feb;98(2):e18-9. doi: 10.3324/haematol.2012.071050. Epub 2012 Sep 14.
2
Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.阿扎胞苷治疗失败后骨髓增生异常综合征患者的预后预测：北美骨髓增生异常综合征联盟评分系统的验证
Haematologica. 2016 Oct;101(10):e427-e428. doi: 10.3324/haematol.2016.150714.
3
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.阿扎胞苷治疗的骨髓增生异常综合征患者循环原始粒细胞的预后价值
Med Oncol. 2019 Jan 31;36(3):25. doi: 10.1007/s12032-019-1247-3.
4
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.新提出的治疗相关骨髓增生异常综合征预后评分可预测接受阿扎胞苷治疗患者的总生存期和无白血病生存期的显著差异。
Leuk Lymphoma. 2013 Aug;54(8):1786-7. doi: 10.3109/10428194.2012.749406. Epub 2012 Dec 10.
5
Hematology: Azacitidine improves survival in myelodysplastic syndromes.血液学：阿扎胞苷可提高骨髓增生异常综合征患者的生存率。
Nat Rev Clin Oncol. 2009 Sep;6(9):502-3. doi: 10.1038/nrclinonc.2009.125.
6
Myelodysplasia, megakaryocytes, and methylation.骨髓发育异常、巨核细胞与甲基化
Leuk Res. 2004 Aug;28(8):775-6. doi: 10.1016/j.leukres.2004.01.003.
7
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.降低高危骨髓增生异常综合征患者中低甲基化药物治疗失败风险及实用管理建议
Leuk Res. 2014 Dec;38(12):1381-91. doi: 10.1016/j.leukres.2014.09.008. Epub 2014 Sep 22.
8
Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.骨髓增生异常综合征的治疗：阿扎胞苷治疗经验引发的问题
J Clin Oncol. 2002 May 15;20(10):2415-6. doi: 10.1200/JCO.2002.20.10.2415.
9
Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.阿扎胞苷治疗失败的骨髓增生异常综合征患者的预后较差。
Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):711-5. doi: 10.1016/j.clml.2013.07.007. Epub 2013 Sep 17.
10
Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.阿扎胞苷治疗失败后，骨髓增生异常综合征和急性髓系白血病对地西他滨缺乏客观反应。
Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3.
引用本文的文献
1
Are We Ready For "Triplet" Therapy in Higher-Risk MDS?我们是否准备好对高危骨髓增生异常综合征进行“三联”治疗？
Clin Hematol Int. 2023 Nov 3;5(4):88301. doi: 10.46989/001c.88301. eCollection 2023.
2
Azacitidine Omega-3 Self-Assemblies: Synthesis, Characterization, and Potent Applications for Myelodysplastic Syndromes.阿扎胞苷ω-3自组装体：合成、表征及其在骨髓增生异常综合征中的潜在应用
Pharmaceuticals (Basel). 2021 Dec 17;14(12):1317. doi: 10.3390/ph14121317.
3
Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS).再谈阿扎胞苷治疗失败：基于希腊骨髓增生异常综合征研究组（HMDS）骨髓增生异常综合征登记处真实数据的评估
Mediterr J Hematol Infect Dis. 2019 Jul 1;11(1):e2019045. doi: 10.4084/MJHID.2019.045. eCollection 2019.
4
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.鲁索替尼在既往接受过治疗、具有NF-κB激活证据的低危或中危-1骨髓增生异常综合征患者中的I期研究。
Leuk Res. 2018 Oct;73:78-85. doi: 10.1016/j.leukres.2018.09.004. Epub 2018 Sep 14.
5
Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party.我们能否考虑停用骨髓增生异常综合征患者的去甲基化药物：来自韩国血液学会急性髓系白血病/骨髓增生异常综合征工作组的一项回顾性研究
Oncotarget. 2017 May 29;8(45):79414-79424. doi: 10.18632/oncotarget.18258. eCollection 2017 Oct 3.
6
Myelodysplastic Syndromes: Updates and Nuances.骨髓增生异常综合征：最新进展与细微差别
Med Clin North Am. 2017 Mar;101(2):333-350. doi: 10.1016/j.mcna.2016.09.006.
7
Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.阿扎胞苷治疗失败后骨髓增生异常综合征患者的预后预测：北美骨髓增生异常综合征联盟评分系统的验证
Haematologica. 2016 Oct;101(10):e427-e428. doi: 10.3324/haematol.2016.150714.
8
Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.TET2或TP53基因的突变预示着接受去甲基化治疗或干细胞移植的骨髓增生异常综合征患者的生存期较短。
Bone Marrow Transplant. 2015 Aug;50(8):1132-4. doi: 10.1038/bmt.2015.110. Epub 2015 May 11.
9
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.一项关于口服ARRY-614（一种p38丝裂原活化蛋白激酶/血管内皮生长因子受体2双抑制剂）用于低危或中危-1骨髓增生异常综合征患者的I期研究。
Clin Cancer Res. 2015 Mar 1;21(5):985-94. doi: 10.1158/1078-0432.CCR-14-1765. Epub 2014 Dec 5.
10
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.低甲基化药物治疗失败后低危和中危-1骨髓增生异常综合征患者的结局：代表骨髓增生异常综合征临床研究联盟的报告
Cancer. 2015 Mar 15;121(6):876-82. doi: 10.1002/cncr.29145. Epub 2014 Nov 19.
本文引用的文献
1
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.阿扎胞苷治疗失败后高危骨髓增生异常综合征的结局。
J Clin Oncol. 2011 Aug 20;29(24):3322-7. doi: 10.1200/JCO.2011.35.8135. Epub 2011 Jul 25.
2
Hypomethylating agents and other novel strategies in myelodysplastic syndromes.低甲基化药物和骨髓增生异常综合征的其他新策略。
J Clin Oncol. 2011 Feb 10;29(5):516-23. doi: 10.1200/JCO.2010.31.0854. Epub 2011 Jan 10.
3
Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.阿扎胞苷治疗低危骨髓增生异常综合征：一项意大利患者登记项目中 74 例患者的回顾性研究。
Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894.
4
How I treat patients with myelodysplastic syndromes.我如何治疗骨髓增生异常综合征患者。
Blood. 2009 Jun 18;113(25):6296-303. doi: 10.1182/blood-2008-09-038935. Epub 2009 Apr 21.
5
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.世界卫生组织（WHO）髓系肿瘤和急性白血病分类的2008年修订版：基本原理及重要变化
Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8.
6
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.阿扎胞苷三种不同给药方案治疗骨髓增生异常综合征患者的血液学反应
J Clin Oncol. 2009 Apr 10;27(11):1850-6. doi: 10.1200/JCO.2008.17.1058. Epub 2009 Mar 2.
7
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.阿扎胞苷与传统治疗方案治疗高危骨髓增生异常综合征的疗效比较：一项随机、开放标签的III期研究。
Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.
8
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.促红细胞生成素和粒细胞集落刺激因子治疗骨髓增生异常综合征的反应和生存预测因素：GFM研究经验
Blood. 2008 Jan 15;111(2):574-82. doi: 10.1182/blood-2007-06-096370. Epub 2007 Oct 16.
9
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.来那度胺用于除5q缺失外其他核型的输血依赖型、低危和中危-1型骨髓增生异常综合征的2期研究。
Blood. 2008 Jan 1;111(1):86-93. doi: 10.1182/blood-2007-01-068833. Epub 2007 Sep 24.
10
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.来那度胺治疗伴有5号染色体长臂缺失的骨髓增生异常综合征
N Engl J Med. 2006 Oct 5;355(14):1456-65. doi: 10.1056/NEJMoa061292.
Zotero 插件